drugset / Trial / NCT06560112
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Timeline
- Start
- 2024-11-12
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |